The DEAH-box family of RNA-dependent NTPases (DHX) plays a crucial role in RNA metabolism, including processes such as splicing, ribosome biogenesis, and mRNA export from the nucleus. These proteins act as molecular motors that harness the energy from nucleotide hydrolysis to unwind or remodel RNA and RNA-protein complexes. The DHX proteins generally contain conserved motifs that are essential for ATP binding and hydrolysis, as well as RNA binding and unwinding. Through their ATPase and helicase activities, DHX proteins are able to dynamically regulate the structure and function of various RNA molecules and complexes, thereby influencing diverse cellular processes.
The class of molecules known as DEAH-box RNA-dependent NTPase (DHX) Inhibitors is specifically designed to modulate the activity of the DHX family of proteins, which are central to RNA metabolism in the cell. These inhibitors typically target the ATPase or helicase domains of DHX proteins, as these are the functional cores responsible for nucleotide binding, hydrolysis, and the subsequent RNA remodeling activities. Some inhibitors may act by binding directly to the ATPase pocket, thereby ATP from binding and disabling the enzyme's activity. Others may bind to regions of the protein that are essential for RNA interaction, therefore making the protein unable to engage with its natural RNA substrates. Some inhibitors are allosteric in nature and can bind to regions other than the active site, causing conformational changes that make the enzyme less effective or completely inactive.
VOIR ÉGALEMENT...
Items 1 to 10 of 11 total
Afficher:
| Nom du produit | CAS # | Ref. Catalogue | Quantité | Prix HT | CITATIONS | Classement |
|---|---|---|---|---|---|---|
Wortmannin | 19545-26-7 | sc-3505 sc-3505A sc-3505B | 1 mg 5 mg 20 mg | $66.00 $219.00 $417.00 | 97 | |
Inhibiteur de PI3K affectant les voies de traitement de l'ARN en aval. | ||||||
Cycloheximide | 66-81-9 | sc-3508B sc-3508 sc-3508A | 100 mg 1 g 5 g | $40.00 $82.00 $256.00 | 127 | |
Inhibe la synthèse des protéines et affecte indirectement le traitement de l'ARN. | ||||||
SB 431542 | 301836-41-9 | sc-204265 sc-204265A sc-204265B | 1 mg 10 mg 25 mg | $80.00 $212.00 $408.00 | 48 | |
Inhibe JNK, qui joue un rôle dans l'épissage de l'ARN. | ||||||
Akt Inhibitor IV | 681281-88-9 | sc-203809 sc-203809A | 5 mg 25 mg | $173.00 $695.00 | 42 | |
Inhibe Akt, qui est impliqué dans le traitement de l'ARN. | ||||||
SP600125 | 129-56-6 | sc-200635 sc-200635A | 10 mg 50 mg | $40.00 $150.00 | 257 | |
Inhibiteur de la JNK pouvant affecter l'épissage de l'ARN. | ||||||
Cisplatin | 15663-27-1 | sc-200896 sc-200896A | 100 mg 500 mg | $76.00 $216.00 | 101 | |
Influence la fonction des hélicases à ARN comme DDX38 en causant des dommages à l'ADN. | ||||||
Fluorouracil | 51-21-8 | sc-29060 sc-29060A | 1 g 5 g | $36.00 $149.00 | 11 | |
Intervient indirectement dans l'activité de l'ARN hélicase en perturbant le métabolisme des nucléotides. | ||||||
Etoposide (VP-16) | 33419-42-0 | sc-3512B sc-3512 sc-3512A | 10 mg 100 mg 500 mg | $32.00 $170.00 $385.00 | 63 | |
Inhibiteur de la topoisomérase II affectant potentiellement le traitement de l'ARN. | ||||||
2′-Deoxy-2′,2′-difluorocytidine | 95058-81-4 | sc-275523 sc-275523A | 1 g 5 g | $56.00 $128.00 | ||
Intervient dans la synthèse et la réparation de l'ADN, en affectant les hélicases de l'ARN comme DDX38. | ||||||
Camptothecin | 7689-03-4 | sc-200871 sc-200871A sc-200871B | 50 mg 250 mg 100 mg | $57.00 $182.00 $92.00 | 21 | |
Inhibiteur de la topoisomérase I qui cause des dommages à l'ADN en affectant les hélicases ARN comme DDX38. | ||||||